Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma

被引：1
|
作者：
Fukumoto, Takeshi [1 ]
Horita, Nobuyuki [2 ]
机构：
[1] Kobe Univ, Grad Sch Med, Dept Internal Related, Div Dermatol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan
[2] Yokohama City Univ, Grad Sch Med, Dept Pulmonol, Yokohama, Kanagawa, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2021年 / 147卷
关键词：
STAGE IV MELANOMA; DOUBLE-BLIND; IPILIMUMAB; NIVOLUMAB; PLACEBO;
D O I：
10.1016/j.ejca.2021.01.031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：140 / 141
页数：2
相关论文
共 50 条
  • [21] Elective Discontinuation of Checkpoint Inhibitor Therapy in Patients with advanced Melanoma
    Persa, O. D.
    Schatton, K.
    Ruebben, A.
    Berking, C.
    Erdmann, M.
    Schlaak, M.
    Mauch, C.
    Steeb, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 40 - 40
  • [22] Successful Treatment of an Immune-Mediated Colitis Induced by Checkpoint Inhibitor Therapy in a Patient with Advanced Melanoma
    Paparoupa, Maria
    Stupperich, Sophie
    Goerg-Reifenberg, Lisa
    Wittig, Andreas
    Schuppert, Frank
    CASE REPORTS IN GASTROENTEROLOGY, 2020, 14 (03) : 554 - 560
  • [23] The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma
    Dimitriou, Florentia
    Urner-Bloch, Ursula
    Eggenschwiler, Corinne
    Mitsakakis, Nicholas
    Mangana, Joanna
    Dummer, Reinhard
    Urner, Martin
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 215 - 223
  • [24] The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
    Wang, Chengdi
    Li, Jingwei
    Zhang, Qiran
    Wu, Jiayang
    Xiao, Yuxuan
    Song, Lujia
    Gong, Hanlin
    Li, Yalun
    BMC CANCER, 2021, 21 (01)
  • [25] The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
    Chengdi Wang
    Jingwei Li
    Qiran Zhang
    Jiayang Wu
    Yuxuan Xiao
    Lujia Song
    Hanlin Gong
    Yalun Li
    BMC Cancer, 21
  • [26] Immune Checkpoint Therapy in Melanoma
    Callahan, Margaret K.
    CANCER JOURNAL, 2016, 22 (02): : 73 - 80
  • [27] Single-center Experience in Immune Checkpoint Inhibitor Therapy in advanced Squamous Cell Carcinoma
    Moussa, R.
    Mitzel-Rink, H.
    Dudda, M.
    Nikfarjam, U.
    Pawlowski, J.
    Grabbe, S.
    Loquai, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 75 - 76
  • [28] Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma
    Esmaeli, Bita
    Ogden, Tyler
    Nichols, Matthew
    Lu, Tracy
    Debnam, J. Matthew
    Dimitriou, Florentia
    Mcquade, Jennifer
    Oliva, Isabella C. Glitza
    MELANOMA RESEARCH, 2025, 35 (02) : 130 - 144
  • [29] Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
    Alexander C. J. van Akkooi
    Lisanne P. Zijlker
    Michel W. J. M. Wouters
    BioDrugs, 2022, 36 : 373 - 380
  • [30] REPRODUCTIVE IMPACT OF IMMUNE CHECKPOINT INHIBITOR THERAPY IN WOMEN WITH MELANOMA.
    Rhodes, Quinn
    Woodard, Terri L.
    Roth, Michael
    Detti, Laura
    Shott, Susan
    McKenzie, Laurie
    FERTILITY AND STERILITY, 2024, 122 (04) : E307 - E307
12345